In the published article, there was an error. The conclusions of the article should be more cautionary and provide a more objective stance on the benefits and risks of this drug and its use. As such, a correction has been made to the Conclusion, final sentence. The original sentence reads as follows: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, pointing out that significant benefits outweigh potential cardiac risks.”
The corrected sentence appears below: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, suggesting that benefits might outweigh potential cardiac risks, although this will need to be established in targeted investigations.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
fenfluramine, pharmacoresistant epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, anti-seizure medication (ASM)
Citation
Dini G, Tulli E, Dell’Isola GB, Mencaroni E, Di Cara G, Striano P and Verrotti A (2023) Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine. Front. Pharmacol. 13:1116575. doi: 10.3389/fphar.2022.1116575
Received
05 December 2022
Accepted
21 December 2022
Published
05 January 2023
Volume
13 - 2022
Edited and reviewed by
Annalisa Capuano, University of Campania Luigi Vanvitelli, Italy
Updates
Copyright
© 2023 Dini, Tulli, Dell’Isola, Mencaroni, Di Cara, Striano and Verrotti.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gianluca Dini, gianlucadini90@gmail.com
This article was submitted to Obstetric and Pediatric Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.